- Home
- NYC vs CASI Comparison
NYC vs CASI Comparison
Compare NYC & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NYC | CASI |
|---|---|---|
| Founded | 2013 | 1991 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.4M | 24.9M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | NYC | CASI |
|---|---|---|
| Price | $7.58 | $1.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 5.1K | ★ 30.5K |
| Earning Date | 11-19-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $51,688,000.00 | $26,846,000.00 |
| Revenue This Year | $8.40 | N/A |
| Revenue Next Year | $1.62 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.72 |
| 52 Week Low | $7.03 | $0.93 |
| 52 Week High | $16.30 | $3.97 |
Technical Indicators
Market Signals| Indicator | NYC | CASI |
|---|---|---|
| Relative Strength Index (RSI) | 35.57 | 28.88 |
| Support Level | $7.03 | $0.93 |
| Resistance Level | $7.85 | $1.25 |
| Average True Range (ATR) | 0.47 | 0.09 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 17.77 | 8.91 |
Price Performance
Historical ComparisonAbout NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.